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Madalene A Earp1, Angela Brooks-Wilson1,2,7*, Linda Cook3,4,5† and Nhu Le6†Abstract
Background: Mitochondria are the site of oxidative phosphorylation, a process which generates reactive oxygen
species (ROS). Elevated ROS levels can lead to oxidative stress, a cellular state implicated in carcinogenesis. It is
hypothesized that alternations in mitochondrial (MT) DNA, including heritable MT single nucleotide polymorphisms
(MT-SNPs), have the potential to change the capacity of MT function, leading to increased oxidative stress and
cancer risk. We investigated if common MT-SNPs and/or haplogroups and are associated with invasive serous
ovarian cancer (OvCa) risk.
Methods: A panel of 64 MT-SNPs designed to tag all common variation in the European MT genome (minor allele
frequency (MAF) >1%, r^2 >0.8) was genotyped in study participants of European descent using the Sequenom
MassARRAY iPlex Gold® system (Sequenom Inc, CA, USA). Invasive serous OvCa cases (n = 405) and frequency age-
matched controls (n = 445) were drawn from a population-based case-control study of OvCa in western Canada.
Binary logistic regression was used to estimate the odds ratio (OR) and 95% confidence intervals (C.I.) for carriage of
the minor versus major allele by case-control status. MitoTool was used to test the relationship between European
haplogroup status and case-control status using Fisher’s exact test.
Results: The most significant disease-SNP association was for rs2857285, a synonymous MT-SNP in ND4 (OR = 4.84,
95% CI: 1.03–22.68, P = 0.045). After adjustment for multiple testing using a Bonferroni correction of the Type 1 error
this MT-SNP was not significant. No other MT-SNP had a P-value < 0.05. European haplogroup status was not
associated with case status. Most MT-SNPs (73%) genotyped had a MAF <5%.
Conclusion: Common European MT-SNPs (MAF > 5%) and haplogroups were not associated with invasive serous
OvCa risk in this study; however, most European MT-SNPs have a low MAF (<5%), which we were underpowered to
adequately assess. Larger studies are needed to clarify the role of low MAF MT-SNPs (MAF < 5%) in invasive serous
OvCa risk.
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Recent genome-wide association studies (GWAS) have re-
vealed several loci associated with epithelial ovarian cancer
(OvCa) risk [1-3]; however, much of the heritable risk for
this disease remains unexplained. The mitochondrial (MT)
genome is an underexplored potential source of OvCa risk.* Correspondence: abrooks-wilson@bcgsc.ca
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reproduction in any medium, provided the orThis small (16.6 kb), circular, maternally-inherited genome
encodes 37 genes, all of which are involved in oxidative
phosphorylation (OXPHOS), the process by which humans
produce most of their energy. A byproduct of OXPHOS is
the production of reactive oxygen species (ROS), unstable
compounds which can generate free radicals. Cells are
equipped to manage a certain level of free radical produc-
tion; however, if threshold levels are exceeded, a state of
oxidative stress occurs. In this state, lipids, proteins and
nucleic acids are subject to attack by ROS [4]. It is hypothe-
sized that alternations in MT DNA, including heritable
single nucleotide polymorphisms (SNPs), have the potentiald. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stress and cancer risk [4,5]. We investigated this possibility.
The ovarian surface epithelium (OSE), the site of most
OvCa, is a unique microenvironment in the body. With
each ovulation the OSE experiences a trauma where the
mature follicle ruptures from the ovary. At this site there
are inflammatory mediators and sub-lethal concentra-
tions of ROS ([6,7]). Heritable MT-SNP variation could
act synergistically with the unique conditions of the
OSE, for example, elevated levels of somatic MT-DNA
mutation incurred due to ROS, and explain why OvCa
risk, not all cancer risk, might be elevated by germ line
MT-SNPs. In connection with this, recent work has sug-
gested that certain MT-DNA haplogroups have tissue-
specific and stage-specific roles in modulating cancer
development [8]. Human MT-DNA haplogroups are de-
fined by unique combinations of MT-DNA polymor-
phisms, along discrete maternal lineages due to genetic
drift and/or selection for MT function (return to original).
These mutations must have occurred in oocyte mitochon-
dria as only these MTgenomes are inherited.
Two studies have examined the potential association be-
tween heritable MT-SNPs and OvCa risk [9,10]. Histology-
specific analyses have not yet been done and to our
knowledge no studies have examined the association between
MT-DNA haplogroup and OvCa risk. Therefore, we evalu-
ated the contribution of heritable MT-SNPs and haplogroups
to the risk of developing serous OvCa in European women.
Somatic MT-DNA mutations, for example, those arising in
the OSE, were not assessed by this study.
Methods
Subjects
Study participants were drawn from the Ovarian Cancer
in Alberta and British Columbia (OVAL-BC) study.
OVAL-BC is a population-based case control study started
in 2002 and completed recruitment in 2011. OVAL-BCTable 1 Association between haplogroup status and invasive
Euroeapn Haplogroup-tagging SNPs Alle
Haplogroup
H rs2015062 C
U rs28358571, rs2853499, rs2854122 T, A
J rs2015062, rs2854122, rs28359178 T, C
K rs28358571 C
V rs2015062, rs2853495, rs2853506 T, G
W rs2854122, rs41535848, rs28357684 T, A
X rs2853517, rs2854122, rs28357684 G, T
I rs8896, rs41347846, mt14182 G, C
T rs3088053, rs3926883 A, C
Table is ordered by haplogroup frequency in cases. Haplogroup tagging MT-SNPs a
a total of 671 samples (317 cases and 354 controls) assigned a unique haplogroup.
status. Haplogroup T could not be assigned because rs3926883 was not genotypedaims to investigate ovarian cancer risk associated with
environmental and genetics factors, along with their
interactions. Eligible OVAL-BC cases had incident, histo-
logically confirmed OvCa identified from the population-
based provincial cancer registries in British Columbia
(BC) and Alberta (AB). Eligible control women were
identified from provincial health care enrollment rosters
(BC and AB) or from a province-wide mammography pro-
gram (BC after 2005). Epidemiological data was collected
through questionnaire/interview from participants who
also provided blood or saliva samples for DNA. OVAL-BC
has a total of 1578 cases and 2222 controls, with 64.9%
and 55.6% response rates respectively. The present analysis
is based on the study population from BC only. This study
was approved by the joint Clinical Research Ethics Board
of the BC Cancer Agency and the University of BC. All
subjects gave written informed consent.
Cases selected for this study (n = 405) were European
women diagnosed with primary invasive serous OvCa.
Cases with borderline serous malignancies were excluded
to increase etiological homogeneity. Controls (n = 445)
were European women selected to be frequency matched
by age with cases (by 10 year age bins). Subject ancestry
was determined by self-reported four-grandparent ethni-
city. Participants were not excluded based on a family his-
tory of cancer; BRCA1 and BRCA2 status were unknown.
MT-DNA sequencing
Blood (90% of subjects) or saliva (10% of subjects) served
as the source of genomic DNA. DNA was extracted from
peripheral venous blood using a modified salting out
protocol [11], and from saliva using OraGene kits (DNA
Genotek, PA, USA). A panel of 64 MT-SNPs designed to
tag all common European MT-DNA variation (minor al-
lele frequency (MAF) ≥1%, r2 ≥ 0.8) [12] was genotyped in
participants using the Sequenom MassARRAY iPlex Gold®
system (Sequenom Inc, CA, USA) (primer sequencesserous ovarian cancer risk
le Case/control
proportions
OR (95% CI) P
0.53 / 0.50 1.10 (0.82-1.51) 0.54
, C 0.19 / 0.20 0.94 (0.64-1.39) 0.77
, A 0.10 / 0.09 1.16 (0.70-1.93) 0.61
0.09 / 0.09 0.98 (0.59-1.65) 1.00
, A 0.05 / 0.07 0.63 (0.32-1.23) 0.18
, G 0.02 / 0.02 1.12 (0.41-3.49) 0.79
, G 0.02 / 0.03 0.67 (0.23-1.94) 0.59
, T 0.00 / 0.00 - 1.00
NA / NA - 1.00
nd allele are as reported by Saxena et al., 2006. OR; odd ratio, is calculated for
P is the Fischer’s exact P-value for testing haplogroup frequency and case
. This SNP did not pass quality control. NA is not available.
Table 2 Select characteristics of study participants,
stratified by case-control status
Variable Cases (N, %)
or (Mean, SD)
Controls (N, %)
or (Mean, SD)
N 392 439
Age (y) 60.9 (10.3) 60.2 (10.4)
BMI1 (kg/m2) 25.3 (4.8) 25.9 (4.9)
Parity2
Nulliparous 62 (16) 53 (12)
1-2 pregnancies 146 (37) 179 (41)
3+ pregnancies 184 (47) 207 (47)
Missing 0 (0) 0 (0)
OC use
Never 146 (37) 112 (25)
Ever 245 (63) 327 (75)
Missing 1 (0) 0 (0)
Family history of ovarian
or breast cancer in >1 FDR
No 290 (74) 352 (80)
Yes 87 (22) 75 (17)
Missing 15 (4) 12 (3)
Pack-years smoked3
None 224 (57) 206 (47)
< 20 68 (17) 118 (27)
> 20 98 (25) 113 (26)
Missing 2 (0) 2 (0)
HT use
Never 205 (52) 263 (60)
Ever 187 (48) 176 (40)
Missing 0 (0) 0 (0)
Percentages are rounded and may not add up to 100. Abbreviations used: N,
number of observations; SD, standard deviation; OC, oral contraceptive; HT,
hormone therapy; FDR, first degree relative.
1BMI was calculated using usual adult or current weight for participants.
2Parity was based on the number of births, regardless of outcome.
3Where “None” is < 100 cigarettes during a lifetime.
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at the McGill University’s Génome Québec Innovation
Centre (Montreal, Quebec) according to the manufac-
turer’s protocol [13]. Sequenom’s TyperAnalyzer software
was used to carry out automated genotype calling. MT-
SNPs were not analyzed if: (i) the call rate was <90%, (ii)
they were monomorphic, or (iii) there was >1 sample with
a heterozygous genotype call. Eight SNPs had a call rate
<90%; 6 of these failed genotyping completely. Two SNPs
were monomorphic, and 2 SNPs were heterozygous in >1
sample. Samples were excluded from analysis if the geno-
typing rate was less <90%. Nineteen samples had a geno-
typing rate <90% (13 cases, 6 controls); 12 samples failed
to genotype completely (10 saliva, 2 blood). This resulted
in data for 52 MT-SNPs in 831 unique samples (392 cases
and 439 controls). For 44 pairs of replicate samples (5.3%
replication rate) the concordance rate was 99.7%.
MT-DNA haplogroup assignment
Samples were assigned to one of nine major European
haplogroups (H, I, J, K, T, U, V, W, and X) by inspecting
the alleles present at haplogroup-tagging MT-SNPs
(given in Table 1). The approached used was previously
described by Saxena et al., 2006. Samples that could not
be unambiguously assigned a haplogroup (75 cases, 85
controls) were excluded.
Statistical analysis
Descriptive statistics were generated using means and
standard deviations for continuous variables and frequen-
cies and percent’s for categorical variables. Distributions of
covariates among cases and controls were compared using
t-tests and χ2 tests of independence for continuous and
categorical variables, respectively. Binary logistic regression
was used to estimate the odds ratio (OR) and 95% confi-
dence intervals (C.I.) for carriage of the minor versus major
allele by case-control status. This model was adjusted for
age (by 5 year age bins: <40, 40-44, 45-49, 50-54, 55-59,
60-64, 65-69, >70). Asymptotic P-values (P) and point-wise
empirical P-values (Pemp) (based on 10,000 permutations of
case-control status) were generated to evaluate signifi-
cance. Adjusting for BMI, parity, smoking history, oral
contraceptive (OC) use, hormone therapy (HT) use, and a
family history of ovarian or breast cancer did not influence
our SNP results; therefore, all data are presented without
correction for these variables. Logistic regression analyses
were implement in PLINK (v1.07). MitoTool [14] was used
to analyze the relationship between European haplogroup
status and case-control status using Fisher’s exact test.
Results
Subject characteristics
Characteristics of the 392 cases and 439 controls in-
cluded in the association analyses are given in Table 2.BMI, parity and a family history of breast or ovarian
cancer were not significantly different between cases and
control participants. Controls were more likely to have
used oral contraceptives (“never used” was 37% for cases
and 25% for controls, P = 0.0006), and more likely to
have smoked (57% of cases report “none” versus 47% of
controls, P = 0.006). Cases were more likely to have used
female HT (“ever used” was 48% for cases and 40% for
controls, P = 0.032).
SNP and haplogroup association results
Of the 52 MT-SNPs tested for association with case-
control status, the most significant result was for a syn-
onymous MT-SNP (rs2857285) in ND4 (OR = 4.84, 95%
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Table S1). After adjustment for multiple testing using a
Bonferroni correction of the Type 1 error this MT-SNP
was not significant. rs2857285 was relatively uncom-
mon, detected in 2.3% of cases and 0.5% of controls.
No other SNP tested had a P-value < 0.05. Gene-wide
tests of association were not performed on our MT-SNP
data because of the lack of a significant result, or a result
“suggestive” of significance, in the individual SNP-specific
tests of association.
Among our study participants, 19% (10/52) of SNPs
qualified as ‘rare’ (MAF <0.01 in both cases and con-
trols), and 54% (28/52) had a MAF < 5% (in both cases
and controls). Thus, for most SNPs tested we were
only powered to detect large effects (OR > 2). Associ-
ation results for MT-SNPs with MAF > 5% are given in
Table 3 (results for all MT-SNPs are given in Additional
file 1: Table S1).
We did not detect a significant relationship between
European MT haplogroup (H, U, J, V, K, W, X, I) status
and case status (Table 1). To assess whether MT-SNP
association results were influenced by haplogroup back-
ground, we also performed a logistic regression adjusting
for age and haplogroup. No SNP had a P-value < 0.05
under this model (data not shown).
Discussion
This report explored the hypothesis that inherited MT-
SNPs and/or haplogroup influence invasive serous OvCa
risk. The analysis focused on a panel of MT-SNPs previ-
ously described to tag all common variants observed inTable 3 MT-SNP-invasive serous ovarian cancer risk associatio
SNP ID BP Major/minor allele Ca
rs2853517 mt709 709 G/A
rs41352944 mt930 930 C/T
rs28358571 mt1189 1189 T/C
rs3928306 mt3010 3010 C/T
rs2015062 mt7028 7028 A/G
rs2853825 mt9477 9477 G/A
rs2853495 mt11719 11719 A/G
rs3088053 mt11812 11812 A/G
rs2853499 mt12372 12372 C/T
rs2854122 mt12705 12705 G/A
rs2853504 mt14793 14793 T/C
rs28357681 mt14798 14798 A/G
rs28357684 mt15043 15043 G/A
rs2853510 mt15924 15924 A/G
Sorted by mitochondrial base-pair position. ID is SNP as reported by Saxena et al., 2
[Accessed 15 Nov, 2012]. BP, mitochondrial base-pair position according to the revi
observations; OR, odds ratio; 95% CI, 95% confidence interval. OR and 95% CI are fo
asymptotic P-value for testing MT-SNP effect significance; Pemp is empirical point-withe European population (MAF > 1%, r2 > 0.8), and was
intended to exhaustively examine the entire MT genome
for association with invasive serous OvCa risk. For the
52 MT-SNPs tested we found little evidence of associ-
ation with invasive serous OvCa risk; however, because
12 MT-SNPs were not examined (having failed genotyp-
ing) our analysis was not as exhaustive as intended. We
found no association between European MT haplogroup
and invasive serous OvCa risk.
We found that most MT-SNPs (73%) were relatively
uncommon (MAF <5%); thus, only those conferring
large OvCa risk (OR > 2) would be reliably detected by
our study, and these do not appear to exist. The MAF
estimates observed in our study are consistent with pre-
vious studies performed in Europeans using this SNP
panel [12,15]. A larger sample size is needed to test
these lower MAF MT-SNPs for association with invasive
serous OvCa risk. For example, approximately 5000
cases and controls would be needed to detect an OR of
2.0 for MT-SNPs with a MAF around 1%.
Two previous studies have examined the association
between inherited variation in the MT genome and
OvCa risk. The first was a small study performed on
women of Chinese descent [10], and tested 1 MT-DNA
SNP (16189T > C) for association with OvCa risk in 53
cases (histological subtype not specified) and 107 con-
trols. No association was detected. The second was a
much larger study performed in on Caucasian women
[9], and tested 128 MT-SNPs for association with OvCa
risk in 1,815 cases (histological subtypes combined) and
1,900 controls. The MT-SNPs tested were those foundn results (MT-SNPs MAF >5%)
se/control MAF N OR (95% CI) P Pemp
0.167 / 0.153 830 1.10 (0.76-1.60) 0.61 0.86
0.056 / 0.043 831 1.30 (0.69-2.46) 0.41 0.55
0.077 / 0.077 831 0.98 (0.59-1.64) 0.94 1.00
0.209 / 0.212 831 1.01 (0.72-1.41) 0.96 1.00
0.408 / 0.428 831 0.93 (0.70-1.23) 0.60 0.64
0.105 / 0.084 830 1.27 (0.80-2.04) 0.31 0.38
0.457 / 0.456 831 1.01 (0.76-1.33) 0.97 1.00
0.079 / 0.075 831 1.06 (0.63-1.78) 0.82 0.73
0.249 / 0.239 825 1.05 (0.76-1.45) 0.77 0.86
0.097 / 0.097 795 1.01 (0.63-1.62) 0.97 1.00
0.054 / 0.055 831 1.00 (0.54-1.82) 0.99 1.00
0.154 / 0.169 829 0.90 (0.62-1.31) 0.59 0.73
0.064 / 0.062 829 1.06 (0.60-1.88) 0.83 0.86
0.066 / 0.068 831 0.97 (0.56-1.68) 0.91 1.00
006, available at: http://www.broadinstitute.org/mpg/tagger/mito.html
sed Cambridge reference sequence; MAF, minor allele frequency; N, number of
r logistic regression adjusting for age at diagnosis or interview. P is the
de P-value, implement in PLINK (v1.07).
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In this study, one MT-SNP in the gene MT-CO1 (COX1,
T6777C), was reported to decrease OvCa risk (OR =
0.68, 95% CI: 0.51-0.92, P = 0.006). Unfortunately, this
SNP failed to genotype; thus, we are unable to provide
additional evidence for or against its association with
OvCa risk. The most associated MT-SNP reported by
our study, rs2857285, was not genotyped by Permuth-
Wey et al. [9]; hence, additional information on this SNP
is not available from this source.
The greatest strength of this study was the population-
based collection of European women with recently col-
lected, detailed epidemiological data, and available high
quality DNA samples. This study’s greatest limitation
was power. Due to small sample size this study was only
powered to reliably detect moderate to large MT-SNP
effect sizes. MT-SNPs associated with small effects on
OvCa risk, and MT-SNPs with low MAF would not be
reliably detected. A further limitation was the potential
for population stratification given principal components
(PCs) representing European ancestry were not available
for all study participants and were not included in our
analyses. Subsequent, in an independent study 50% of
our participants were confirmed to be of >90% European
ancestry using the program LAMP (Pharoah et al., in
submission). Although the remaining 50% were not ex-
amined, we see no reason why their ancestry would dif-
fer. When individuals with PCs (N = 408) were analyzed
adjusting for the first 5 eigenvalues from the PC analysis,
no MT-SNP-cancer associations had a P-value <0.05.
Thus, we do not anticipate that inclusion of PC’s would
change the conclusion of this study.Conclusion
There is relatively little evidence that inherited MT-SNP
variation contributes to invasive serous OvCa risk in
European women. Conceivably, rare MT-SNP variants
(MAF <1%) conferring large OvCa risk account for a por-
tion of the heritable risk of this disease. A full genome se-
quencing approach in a large study cohort could explore
this possibility. Furthermore, these studies have the poten-
tial to identify indels and heteroplasmy, which have yet to
be examined with respect to heritable OvCa risk.Additional file
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